Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound and substituent technology, applied in the field of amide derivatives as GK activators, can solve the problem that weight loss is not a therapeutic target
Inactive Publication Date: 2009-07-01
NOVO NORDISK AS
View PDF44 Cites 12 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Unfortunately, initial weight loss is not a preferred treatment goal
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0525] 2-(3,4-Dichlorophenoxy)hexyl was prepared from ethyl 2-hydroxyhexanoate (0.32 g, 2.0 mmol) and 3,4-dichlorophenol (0.39 g, 2.4 mmol) according to general procedure A Acid (0.3 g, 55%). A solution of this acid (69 mg, 0.25 mmol) in THF (3 ml) was reacted with 2-aminothiazole (60 mg, 0.6 mmol) according to general procedure E to give 2-(3,4-dichlorophenoxy)-hexyl Acid thiazol-2-ylamide (64 mg, 72%).
[0531] 2-(4-Fluorophenoxy)hexanoic acid (0.23 g, 52 %). A solution of this acid (56 mg, 0.25 mmol) in THF (3 ml) was reacted with 2-aminothiazole (60 mg, 0.6 mmol) following general procedure E to afford 2-(4-fluorophenoxy)-N-1, 3-Thiazol-2-ylhexanamide (58 mg, 76%).
[0537] 2-(4-Methoxyphenoxy)hexanoic acid ( 0.23 g, 48%). A solution of this acid (60 mg, 0.25) in THF (3 ml) was reacted with 2-aminothiazole (60 mg, 0.6 mmol) via Method E to afford 2-(4-methoxyphenoxy)-N-1 , 3-thiazol-2-ylhexanamide (130 mg, 82%).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The present invention relates to compounds of general formula (I), which are activators of glucokinase (GK), and which may be suitable for the treatment, treatment, control and auxiliary treatment of such diseases: wherein increasing the activity of glucokinase is Beneficial, such as IGT, syndrome X, type 2 diabetes, type 1 diabetes, dyslipidemia, hyperlipidemia, hypertension and obesity.
Description
field of invention [0001] The present invention relates to compounds, which are activators of glucokinase (GK), which may be suitable for the treatment, management, management or adjunctive treatment of such diseases, in which case glucose Kinase activity is beneficial. Background of the invention [0002] Diabetes is characterized in that impaired glucose metabolism in diabetic patients proves itself to be caused by elevated blood glucose levels. The underlying defect causes diabetes to fall into two main categories: type 1 diabetes, or insulin-dependent diabetes mellitus (IDDM), which results when a patient lacks the insulin-producing beta cells in their pancreas; and type 2 diabetes, or non-insulin-dependent diabetes (NIDDM), which occurs in patients when impaired beta cell function occurs in addition to a cluster of other abnormalities. [0003] Patients with type 1 diabetes are currently treated with insulin, while most patients with type 2 diabetes are treated with s...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more